Literature DB >> 18348317

Fast detection of MYCN copy number alterations in brain neuronal tumors by real-time PCR.

S G Malakho1, A Korshunov, A M Stroganova, A B Poltaraus.   

Abstract

Increased MYCN gene copy number is a characteristic property of neurogenic tumors. Fluorescence in situ hybridization (FISH) and array-based comparative genomic hybridization (array-CGH) are traditionally used to determine MYCN amplification for tumor stratification. A unique ability of real-time quantitative polymerase chain reaction (qPCR) to determine gene copy number, even within a small percent of observed tumor cells, and can be more appropriate. MYCN genomic copy number from 44 human brain tumors (22 medulloblastomas and 22 neurocytomas) was determined by means of FISH, array-CGH, and qPCR. By qPCR, with the original set of oligonucleotides, 17 out of 44 (38.6%) tumors were found to contain a 1.3- to 2.9-fold increase of MYCN defined as low-level gain. An absolute qPCR method was used to get high accuracy of results. Strong correlation was observed between the three methods: for medulloblastomas, r=1 (P<0.01) between FISH and array-CGH and r=0.92 (P<0.01) between qPCR and FISH/array-CGH. For neurocytomas, r=0.9 (P<0.01) between FISH and array-CGH and r=0.34/0.43 (P<0.01) between qPCR and FISH/array-CGH. Absolute qPCR assays possess high precision compared to other conventional methods and can be used for accurate and quickness detection of MYCN status (low-level gene gain and amplification). (Copyright ) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18348317      PMCID: PMC6649233          DOI: 10.1002/jcla.20232

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  24 in total

1.  Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay.

Authors:  Katleen De Preter; Frank Speleman; Valérie Combaret; John Lunec; Geneviève Laureys; Bert H J Eussen; Nadine Francotte; Julian Board; Andy D J Pearson; Anne De Paepe; Nadine Van Roy; Jo Vandesompele
Journal:  Mod Pathol       Date:  2002-02       Impact factor: 7.842

2.  Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR.

Authors:  John Anderson; Sian Gibson; Dan Williamson; Dyanne Rampling; Catherine Austin; Janet Shipley; Neil Sebire; Penelope Brock
Journal:  Pediatr Blood Cancer       Date:  2006-06       Impact factor: 3.167

3.  Real-time quantitative PCR for the measurement of MYCN amplification in human neuroblastoma with the TaqMan detection system.

Authors:  C C Raggi; M L Bagnoni; G P Tonini; M Maggi; G Vona; P Pinzani; K Mazzocco; B De Bernardi; M Pazzagli; C Orlando
Journal:  Clin Chem       Date:  1999-11       Impact factor: 8.327

4.  N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation.

Authors:  Paul S Knoepfler; Pei Feng Cheng; Robert N Eisenman
Journal:  Genes Dev       Date:  2002-10-15       Impact factor: 11.361

5.  Gene amplification in PNETs/medulloblastomas: mapping of a novel amplified gene within the MYCN amplicon.

Authors:  M C Frühwald; M S O'Dorisio; L J Rush; J L Reiter; D J Smiraglia; G Wenger; J F Costello; P S White; R Krahe; G M Brodeur; C Plass
Journal:  J Med Genet       Date:  2000-07       Impact factor: 6.318

6.  Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping.

Authors:  J Bayani; M Zielenska; P Marrano; Y Kwan Ng; M D Taylor; V Jay; J T Rutka; J A Squire
Journal:  J Neurosurg       Date:  2000-09       Impact factor: 5.115

7.  Central neurocytoma: morphological, flow cytometric, polymerase chain reaction, fluorescence in situ hybridization, and karyotypic analyses. Case report.

Authors:  V Jay; V Edwards; E Hoving; J Rutka; L Becker; M Zielenska; I Teshima
Journal:  J Neurosurg       Date:  1999-02       Impact factor: 5.115

Review 8.  Neuroblastoma: biology and molecular and chromosomal pathology.

Authors:  Manfred Schwab; Frank Westermann; Barbara Hero; Frank Berthold
Journal:  Lancet Oncol       Date:  2003-08       Impact factor: 41.316

9.  Gene expression levels assessed by oligonucleotide microarray analysis and quantitative real-time RT-PCR -- how well do they correlate?

Authors:  Peter B Dallas; Nicholas G Gottardo; Martin J Firth; Alex H Beesley; Katrin Hoffmann; Philippa A Terry; Joseph R Freitas; Joanne M Boag; Aaron J Cummings; Ursula R Kees
Journal:  BMC Genomics       Date:  2005-04-27       Impact factor: 3.969

10.  cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.

Authors:  Qing-Rong Chen; Sven Bilke; Jun S Wei; Craig C Whiteford; Nicola Cenacchi; Alexei L Krasnoselsky; Braden T Greer; Chang-Gue Son; Frank Westermann; Frank Berthold; Manfred Schwab; Daniel Catchpoole; Javed Khan
Journal:  BMC Genomics       Date:  2004-09-20       Impact factor: 3.969

View more
  2 in total

1.  Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma.

Authors:  Karel Zitterbart; Hana Filkova; Lenka Tomasikova; Eva Necesalova; Iva Zambo; Dagmar Kantorova; Iva Slamova; Vladimira Vranova; Dita Zezulkova; Martina Pesakova; Zdenek Pavelka; Renata Veselska; Petr Kuglik; Jaroslav Sterba
Journal:  J Neurooncol       Date:  2010-07-08       Impact factor: 4.130

2.  Clinical Importance of Myc Family Oncogene Aberrations in Epithelial Ovarian Cancer.

Authors:  MoonSun Jung; Amanda J Russell; Catherine Kennedy; Andrew J Gifford; Kylie-Ann Mallitt; Siva Sivarajasingam; David D Bowtell; Anna DeFazio; Michelle Haber; Murray D Norris; Michelle J Henderson
Journal:  JNCI Cancer Spectr       Date:  2018-11-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.